UCB is buying epilepsy-focused Neurona Therapeutics for up to $1.15 billion, underscoring how aggressively big pharma is bidding for late preclinical-to-clinical neurologic assets. The transaction includes $650 million upfront and additional milestone payments tied to development and regulatory progress, with Neurona’s lead program NRTX-1001. The deal lands amid a wave of neuro-focused acquisitions during 2026, as acquirers continue to prioritize CNS mechanisms where differentiation could translate into large patient populations. Neurona’s offer structure also reflects current deal economics that lean on milestone-based risk sharing. Investors will be watching how quickly UCB maps NRTX-1001 into its clinical and regulatory strategy and whether the acquisition accelerates timelines against competing anti-epilepsy development programs.